1. Signaling Pathways
  2. Anti-infection
  3. HIV

HIV

Human immunodeficiency virus

HIV (Human immunodeficiency virus) is a lentivirus (a subgroup of retrovirus) that causes the acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Infection with HIV occurs by the transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk. Within these bodily fluids, HIV is present as both free virus particles and virus within infected immune cells. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages, and dendritic cells. HIV infection leads to low levels of CD4+ T cells through a number of mechanisms, including apoptosis of uninfected bystander cells, direct viral killing of infected cells, and killing of infected CD4+ T cells by CD8 cytotoxic lymphocytes that recognize infected cells. When CD4+ T cell numbers decline below a critical level, cell-mediated immunity is lost, and the body becomes progressively more susceptible to opportunistic infections.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-125494
    Droxinavir hydrochloride
    Inhibitor
    Droxinavir hydrochloride (SC-55389A) is an HIV-1 protease inhibitor. Droxinavir hydrochloride binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir hydrochloride can be used in studies related to human immunodeficiency virus type 1 infection.
    Droxinavir hydrochloride
  • HY-N12047
    Schineolignin C
    Schineolignin C is a Lignan that can be isolated from the fruit of schisandra chinensis. schisandra chinensis has antihepatitis, antitumor, and anti-HIV-1 activities.
    Schineolignin C
  • HY-111964S1
    Lenacapavir-d5
    Inhibitor
    Lenacapavir-d5 (GS-6207-d5) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection.
    Lenacapavir-d<sub>5</sub>
  • HY-12109
    L-870810
    Inhibitor
    L-870810 is a potent HIV-1 IN chain transfer inhibitor with antiviral activity.
    L-870810
  • HY-146338
    RPR103611
    Inhibitor
    RPR103611, the betulinic acid derivative, is a potent HIV-1 entry inhibitor with IC50s of 80, 0.27, and 0.17 for CCR5-tropic virus YU2, CXCR4-tropic virus NL4-3 and dual tropic virus 89.6, respectively.
    RPR103611
  • HY-155114
    HIV-1 inhibitor-59
    Inhibitor
    HIV-1 inhibitor-59 (Compound I-5b) is a HIV-1 inhibitor, with EC50s of 5.62-171 nM against the wild-type (WT) and mutant HIV-1 strains. HIV-1 inhibitor-59 has moderate RT enzyme inhibitory activity (IC50: 0.094-12.0 μM).
    HIV-1 inhibitor-59
  • HY-N10958
    Wikstrol A
    Inhibitor
    Wikstrol A is a potent antifungal, antimitotic and anti-HIV-1 Agent. Wikstrol A induces morphological deformation of P. oryzae mycelia with an MMDC value of 70.1 µM. Wikstrol A shows activity against microtubule polymerization with an IC50 value of 131 µM. Wikstrol A shows anti-HIV-1 activity with an IC50 value of 67.8 µM.
    Wikstrol A
  • HY-144123
    HIV-1 inhibitor-16
    Inhibitor
    HIV-1 inhibitor-16 (compound 7a) is a highly potent HIV-1 inhibitor with an EC50 value of 1.3 nM for HIV-1 WT. HIV-1 inhibitor-16 also has certain inhibitory activity against HIV-1 K103N, E138K, Y181C and L100I strains with EC50s of 5.4 nM, 9.2 nM, 22 nM and 35 nM. HIV-1 inhibitor-16 has favorable solubility and liver microsome stability, and does not exhibit apparent CYP enzymatic inhibitory activity or acute toxicity.
    HIV-1 inhibitor-16
  • HY-N13716
    Lucidenic acid O
    Inhibitor
    Lucidenic acid O is a terpene compound, is a DNA polymerases inhibitor. Lucidenic lactone inhibits calf DNA polymerase-α, rat DNA polymerase-β, and HIV-1 reverse transcriptase with IC50 values of 42 μM, 99 μM, and 69 μM, respectively.
    Lucidenic acid O
  • HY-P2200
    Siamycin I
    Inhibitor
    Siamycin I (BMY-29304), a 21-residue tricyclic peptide, is a secondary metabolite in actinomycetes. Siamycin I is a HIV fusion inhibitor with ED50s of 0.05 to 5.7 μM for acute HIV type 1 (HIV-1) and HIV-2 infections. Siamycin I inhibits the gelatinase and gelatinase biosynthesis-activating pheromone (GBAP) signaling via the FsrC-FsrA two-component regulatory system in a noncompetitive manner. Siamycin I suppresses the expression of both fsrBDC and gelE-sprE transcripts. Siamycin I, a lasso peptide, interacts with lipid II and inhibits cell wall biosynthesis. Siamycin I, an antibiotic, has the potential for enterococcal infections research.
    Siamycin I
  • HY-10353S
    Raltegravir-d4
    Inhibitor
    Raltegravir-d4 is deuterium labeled Raltegravir. Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection.
    Raltegravir-d<sub>4</sub>
  • HY-P11157
    DrkBiT
    DrkBiT is a membrane-impermeable peptide competing with HiBiT. DrkBiT binds to LgBiT. DrkBiT can be used in the research of HIV-1 infection.
    DrkBiT
  • HY-W009783A
    Deoxymannojirimycin hydrochloride
    Inhibitor
    Deoxymannojirimycin hydrochloride is a selective class I α1,2-mannosidase inhibitor with an IC50 of 20 μM. Deoxymannojirimycin hydrochloride is also a N-linked glycosylation inhibitor. Deoxymannojirimycin hydrochloride has antiviral activity against HIV‐1 strains . Deoxymannojirimycin hydrochloride increases high mannose structures. Deoxymannojirimycin hydrochloride can be used for the study of liver cancer and colon cancer.
    Deoxymannojirimycin hydrochloride
  • HY-159150
    HIV-1 inhibitor-71
    Inhibitor
    HIV-1 inhibitor-71 (compound 2a) blocks the transport of endocytosed HIV-1 particles into nuclear envelope invagination (NEIs) that can inhibit productive infection.
    HIV-1 inhibitor-71
  • HY-152132
    CCR5 antagonist 3
    Inhibitor
    CCR5 antagonist 3 (Compound 26) is a CCR5 antagonist with an IC50 of 15.90 nM. CCR5 antagonist 3 shows broad-spectrum anti-HIV-1 activities.
    CCR5 antagonist 3
  • HY-150697
    HIV-1 inhibitor-44
    Inhibitor
    HIV-1 inhibitor-44 (compound 11l) is a HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-44 shows inhibitory activity against wild-type HIV-1 strain with an EC50 value of 0.209 μM.
    HIV-1 inhibitor-44
  • HY-138562
    HIV-1 Nef-IN-1
    Inhibitor 98.60%
    HIV-1 Nef-IN-1 is an HIV-1 Nef protein inhibitor that efficiently competes for Nef-SH3Hck interactions with a Kd of 6.7 μM.
    HIV-1 Nef-IN-1
  • HY-N0492AR
    α-Lipoic Acid sodium (Standard)
    Inhibitor
    α-Lipoic Acid (sodium) (Standard) is the analytical standard of α-Lipoic Acid (sodium). This product is intended for research and analytical applications. α-Lipoic Acid (Thioctic acid) sodium is an antioxidant, which is an essential cofactor of mitochondrial enzyme complexes. α-Lipoic Acid sodium inhibits NF-κB-dependent HIV-1 LTR activation. α-Lipoic Acid sodium induces endoplasmic reticulum (ER) stress-mediated apoptosis in hepatoma cells. α-Lipoic Acid sodium can be used with CPUL1 (HY-151802) to construct the self-assembled nanoaggregate CPUL1-LA NA, which has improved antitumor efficacy than CPUL1.
    α-Lipoic Acid sodium (Standard)
  • HY-132572
    HIV-1 integrase inhibitor 9
    Inhibitor
    HIV-1 integrase inhibitor 9 (compound 8a) is a potent HIV-1 RNase H inhibitor with an IC50 of 12.3 μM. HIV-1 integrase inhibitor 9 shows an antiviral activity.
    HIV-1 integrase inhibitor 9
  • HY-105394
    BEA 005
    Inhibitor
    BEA 005 is an antivirus agent. BEA 005 can block early systemic and mucosal infections with SIV and HIV-2.
    BEA 005
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.